vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $11.5M, roughly 1.2× TRANSACT TECHNOLOGIES INC). On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 11.9%). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
FENC vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $11.5M |
| Net Profit | $-4.8M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -18.5% | -10.1% |
| Net Margin | -34.7% | — |
| Revenue YoY | 73.8% | 11.9% |
| Net Profit YoY | -141.1% | — |
| EPS (diluted) | $-0.17 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $11.5M | ||
| Q3 25 | $12.5M | $13.2M | ||
| Q2 25 | $9.7M | $13.8M | ||
| Q1 25 | $8.8M | $13.1M | ||
| Q4 24 | $7.9M | $10.2M | ||
| Q3 24 | $7.0M | $10.9M | ||
| Q2 24 | $7.3M | $11.6M | ||
| Q1 24 | $25.4M | $10.7M |
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-638.0K | $15.0K | ||
| Q2 25 | $-3.2M | $-143.0K | ||
| Q1 25 | $-1.2M | $19.0K | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-5.7M | $-551.0K | ||
| Q2 24 | $-5.6M | $-319.0K | ||
| Q1 24 | $12.8M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -18.5% | -10.1% | ||
| Q3 25 | -1.5% | 0.1% | ||
| Q2 25 | -28.3% | -1.9% | ||
| Q1 25 | -9.2% | -0.1% | ||
| Q4 24 | -11.8% | -10.3% | ||
| Q3 24 | -74.6% | -7.7% | ||
| Q2 24 | -69.4% | -3.8% | ||
| Q1 24 | 54.2% | -12.2% |
| Q4 25 | -34.7% | — | ||
| Q3 25 | -5.1% | 0.1% | ||
| Q2 25 | -32.7% | -1.0% | ||
| Q1 25 | -13.3% | 0.1% | ||
| Q4 24 | -25.0% | — | ||
| Q3 24 | -82.2% | -5.1% | ||
| Q2 24 | -76.5% | -2.8% | ||
| Q1 24 | 50.6% | -9.7% |
| Q4 25 | $-0.17 | $-0.11 | ||
| Q3 25 | $-0.02 | $0.00 | ||
| Q2 25 | $-0.11 | $-0.01 | ||
| Q1 25 | $-0.04 | $0.00 | ||
| Q4 24 | $-0.02 | $-0.80 | ||
| Q3 24 | $-0.21 | $-0.06 | ||
| Q2 24 | $-0.20 | $-0.03 | ||
| Q1 24 | $0.41 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | $31.1M |
| Total Assets | $70.6M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $20.4M | ||
| Q3 25 | $21.9M | $20.0M | ||
| Q2 25 | $18.7M | $17.7M | ||
| Q1 25 | $22.7M | $14.2M | ||
| Q4 24 | $26.6M | $14.4M | ||
| Q3 24 | $40.3M | $11.3M | ||
| Q2 24 | $43.1M | $11.1M | ||
| Q1 24 | $51.2M | $10.6M |
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $31.1M | ||
| Q3 25 | $-4.5M | $31.8M | ||
| Q2 25 | $-7.5M | $31.3M | ||
| Q1 25 | $-5.9M | $30.9M | ||
| Q4 24 | $-5.9M | $30.6M | ||
| Q3 24 | $-5.2M | $38.4M | ||
| Q2 24 | $-1.4M | $38.5M | ||
| Q1 24 | $3.0M | $38.6M |
| Q4 25 | $70.6M | $44.8M | ||
| Q3 25 | $49.3M | $45.0M | ||
| Q2 25 | $44.9M | $44.5M | ||
| Q1 25 | $46.4M | $44.2M | ||
| Q4 24 | $44.9M | $44.0M | ||
| Q3 24 | $58.9M | $50.5M | ||
| Q2 24 | $63.2M | $50.4M | ||
| Q1 24 | $69.2M | $51.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $609.0K | ||
| Q3 25 | $1.5M | $3.6M | ||
| Q2 25 | $-3.7M | $3.6M | ||
| Q1 25 | $-4.3M | $-161.0K | ||
| Q4 24 | $-1.5M | $2.4M | ||
| Q3 24 | $-2.2M | $327.0K | ||
| Q2 24 | $-8.4M | $636.0K | ||
| Q1 24 | $39.0M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
